

GITLIFE BIOTECH LTD (IN LIQUIDATION)

Assets For Sale

PROPRIETARY BIO-DIGITAL PLATFORM FOR BIOLOGICAL ASSET TRACEABILITY AND OWNERSHIP MANAGEMENT

OVERVIEW

On behalf of Andrew Little and Gillian Margaret Sayburn of BTG Begbies Traynor (Central) LLP, acting as Joint Liquidators of Gitlife Biotech Ltd (in Liquidation) ("Gitlife" or, the "Company") Gordon Brothers is offering the unique opportunity to acquire the Company's intellectual property assets.

The Company is a UK-developed synthetic biology technology business which has created a proprietary bio-digital platform for biological asset traceability, provenance, ownership verification and collaboration.

The Company developed a suite of software, bioinformatics and molecular biology technologies designed to connect engineered biological assets with their associated digital records, enabling organisations to track, authenticate and manage valuable biological assets throughout their lifecycle.

The technology is centred around CellRepo®, a biological version-control platform, together with proprietary DNA barcoding technologies that create a verifiable link between physical biological assets and their digital history. The technology has potential applications across synthetic biology, biotechnology, industrial biotechnology, biomanufacturing, culture collections, research institutions, biosecurity and intellectual property management.

OPPORTUNITY HIGHLIGHTS

- Proprietary platform for biological asset traceability and ownership verification
- UK and international patent filings relating to DNA barcoding technologies
- Proprietary software, bioinformatics workflows and technical know-how
- Established CellRepo® biological version-control platform
- Applications across synthetic biology, biotechnology and biosecurity sectors
- Portfolio of registered trademarks and associated digital assets
- Strategic technology acquisition opportunity in a high-growth market

ASSETS AVAILABLE

- CellRepo® software platform and associated source code
- DNA barcoding and GenoSignature® intellectual property
- UK and international patent applications
- Proprietary bioinformatics tools and algorithms
- Technical know-how, protocols and development materials
- Registered trademark portfolio and associated brand assets
- Domain names and digital infrastructure
- Supporting technical documentation and research materials

Further information and access to the virtual data room can be provided after executing an NDA.

OFFER DEADLINE

Expressions of interest due by 3:00 pm (BST) on Friday 30th October. Offers must be submitted by no later than 3:00 pm (BST) on Friday 6th November.

Please contact:



Jack Brocklebank
Analyst
Intellectual Property
EMEA

jbrocklebank@gordonbrothers.com
+44 (0)7423 704791



Andrew Smith
Manager
Intellectual Property
EMEA

asmith@gordonbrothers.com
+44 (0)7425 755485



GORDONBROTHERS.COM